Clinical factors for choosing active surveillance: an analysis of papillary thyroid microcarcinoma patients with recurrence

被引:0
|
作者
Won, Ho-Ryun [1 ,2 ]
Kim, Min Gyu [1 ]
Kim, Min Soo [1 ]
Chang, Jae Won [1 ,3 ]
Koo, Bon Seok [1 ,3 ]
机构
[1] Chungnam Natl Univ, Dept Otorhinolaryngol Head & Neck Surg, Coll Med, Daejeon, South Korea
[2] Chungnam Natl Univ, Dept Otorhinolaryngol Head & Neck Surg, Sejong Hosp, Sejong, South Korea
[3] Chungnam Natl Univ Hosp, Dept Otolaryngol Head & Neck Surg, Daejeon, South Korea
基金
新加坡国家研究基金会;
关键词
thyroid cancer; papillary thyroid microcarcinoma; active surveillance; recurrence; clinical factor; BRAF MUTATION; CANCER; ASSOCIATION; CARCINOMA;
D O I
10.1530/ETJ-23-0195
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Active surveillance (AS) has been suggested as a management option for low-risk papillary thyroid microcarcinoma (PTMC). However, the currently proposed selection criteria for AS application do not consider various clinical factors. The purpose of this study was to analyze clinical factors related to recurrence that could be confirmed preoperatively in patients who underwent surgery for PTMC and to identify factors worth considering when deciding whether to apply AS. Materials and methods: Data were collected from patients with PTMC who underwent surgical treatment at Chungnam National University Hospital. A retrospective cohort was established according to the presence or absence of recurrence during the follow-up period. In total, 2717 patients were enrolled, of whom 60 experienced recurrence. Various clinical factors that could be identified before surgery were analyzed. Results: The relationship between various clinical factors that could be confirmed preoperatively and recurrence was confirmed through Cox regression analysis and Kaplan-Meier curve analysis. BRAF mutation and the tall cell variant were significantly more common in patients with recurrence. In patients aged 55 years or older, the risk of recurrence was lower than in younger patients, while the recurrence-free survival (RFS) rate was higher. Conclusion: When choosing between surgical treatment or AS in PTMC patients, additional consideration of the patient's clinical factors, such as age and BRAF mutation status, may be required in addition to the existing criteria.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea
    Kwon, Hyemi
    Oh, Hye-Seon
    Kim, Mijin
    Park, Suyeon
    Jeon, Min Ji
    Kim, Won Gu
    Kim, Won Bae
    Shong, Young Kee
    Song, Dong Eun
    Baek, Jung Hwan
    Chung, Ki-Wook
    Kim, Tae Yong
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (06): : 1917 - 1925
  • [22] Factors affects the implementation of active surveillance therapy for low-risk papillary thyroid microcarcinoma
    Zhang, Xueqi
    Aihaiti, Renaguli
    Teng, Weiping
    Shi, Xiaoguang
    CHINESE MEDICAL JOURNAL, 2024, 137 (15) : 1888 - 1890
  • [23] Factors affects the implementation of active surveillance therapy for low-risk papillary thyroid microcarcinoma
    Zhang Xueqi
    Aihaiti Renaguli
    Teng Weiping
    Shi Xiaoguang
    中华医学杂志英文版, 2024, 137 (15)
  • [24] Active surveillance versus primary surgery for papillary microcarcinoma of the thyroid gland
    Dralle, H.
    Weber, F.
    CHIRURG, 2017, 88 (01): : 71 - 71
  • [25] Active Surveillance May Be the Best Initial Management for Papillary Thyroid Microcarcinoma
    Ito, Yasuhiro
    Miyauchi, Akira
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (07)
  • [26] Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand?
    Jeon, Min Ji
    Kim, Won Gu
    Chung, Ki-Wook
    Baek, Jung Hwan
    Kim, Won Bae
    Shong, Young Kee
    EUROPEAN THYROID JOURNAL, 2019, 8 (06) : 298 - 306
  • [27] Reflecting on Thirty Years of Experience With Active Surveillance for Papillary Thyroid Microcarcinoma
    Mulder, Michelle B.
    Duh, Quan-Yang
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (09)
  • [28] Active Surveillance versus primary Surgery for papillary Microcarcinoma of the Thyroid Gland
    Dralle, H.
    Weber, F.
    CHIRURG, 2019, 90 (Suppl 2): : S110 - S110
  • [29] Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?
    Leboulleux, Sophie
    Tuttle, R. Michael
    Pacini, Furio
    Schlumberger, Martin
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (11): : 933 - 942
  • [30] A retrospective analysis of prognostic factors predictive of lymphnode metastasis and recurrence in thyroid papillary microcarcinoma
    Usluogullari, C. A.
    Onal, E. D.
    Ozdemir, E.
    Ucler, R.
    Kiyak, G.
    Ersoy, P. E.
    Yalcin, S.
    Guler, G.
    Ersoy, R.
    Cakir, B.
    MINERVA ENDOCRINOLOGICA, 2015, 40 (01) : 15 - 22